Market Segmentation Strategies for mRNA COVID-19 Vaccines in Canada: Best Practices in Biomedical Product Development
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The emergence of mRNA vaccine technology during the COVID-19 pandemic has fundamentally transformed vaccine development paradigms, offering unprecedented speed and adaptability in responding to emerging infectious diseases. As described by Pardi et al. (2018), mRNA vaccines represent a paradigm shift in vaccinology by utilizing cellular machinery to produce antigenic proteins. This article examines market segmentation strategies for mRNA-based COVID-19 vaccines within the Canadian healthcare context, addressing the unique challenges of maintaining vaccination coverage in a mature pandemic response environment. According to the Public Health Agency of Canada (2024), over 95 million COVID-19 vaccine doses have been administered nationally. The analysis identifies priority population segments including older adults aged 65 years and above who account for approximately 90% of COVID-19-related deaths (Statistics Canada, 2024), immunocompromised individuals requiring specialized vaccination approaches (Canadian Immunization Research Network, 2023), and healthcare workers with elevated occupational exposure risk. Our framework integrates demographic, epidemiological, behavioral, and healthcare system factors to optimize vaccine allocation and uptake strategies. Future directions emphasize the potential of mRNA platform technology for broader vaccine applications and the importance of maintaining healthcare system resilience through sustained vaccination programs. Keywords: mRNA vaccines, COVID-19, market segmentation, pandemic response, vaccine development, Canadian immunization programs, booster vaccination
Fields of Study & Subjects
Vaccine Coverage and Hesitancy
SARS-CoV-2 and COVID-19 Research
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 26 March 2026
- Language
- EN